Investigator-initiated trials (IITs) are clinical studies designed and managed by an investigator or academic institution rather than a pharmaceutical company. Despite being academically driven, IITs must comply with ICH E6 and applicable GCP regulations to ensure participant safety and data credibility.
What Are Investigator-Initiated Trials?
IITs typically explore scientific questions that may not be prioritized by commercial sponsors, such as comparative effectiveness, rare disease treatments, or off-label uses of approved drugs. In an IIT, the investigator serves the dual role of trial lead and sponsor, assuming responsibility for regulatory submissions, adverse event reporting, trial monitoring, and Trial Master File (TMF) maintenance. Many IITs receive funding from peer-reviewed grants or pharmaceutical company support under collaborative research agreements.
Regulatory Framework
IITs are subject to the same ICH E6 GCP standards as commercially sponsored trials. In the United States, investigators conducting IITs under an Investigational New Drug (IND) application must comply with 21 CFR Parts 50, 56, and 312. In Europe, EU Clinical Trials Regulation (536/2014) applies equally to IITs. Regulatory authorities expect the same level of compliance with informed consent, ethics committee review, and data integrity requirements regardless of the study’s origin.
Key Requirements
The investigator-sponsor must ensure that all GCP requirements are met, including obtaining IRB/Ethics Committee approval, maintaining investigational product accountability, and ensuring adequate trial monitoring. Many academic institutions have Clinical Trial Offices (CTOs) or Good Clinical Practice Units that provide infrastructure and support for IITs. The investigator must also register the trial in a public registry such as ClinicalTrials.gov and comply with results reporting obligations.
Documentation
The documentation burden for IITs is comparable to commercially sponsored trials. The investigator must compile and maintain a complete TMF, including the protocol, investigator’s brochure, regulatory approvals, monitoring records, and essential documents as defined in ICH E6 Section 8. Adequate record retention procedures must be in place, and staff must be trained on GCP and the specific requirements of the trial.
Conclusion
Investigator-initiated trials play a vital role in advancing medical knowledge but carry the full weight of GCP compliance obligations. Academic investigators must recognize their dual responsibilities as investigator and sponsor and seek institutional support where available. Proper planning and infrastructure are essential for conducting IITs that meet regulatory standards.
